In addition, by combining existing biomarkers such as MSI, TMB, and PD-L1, with newly discovered biomarkers, the accuracy of predicting immunotherapy efficacy and patient stratification for colorectal cancer can be improved. This evidence concerns the gene CD274 and colorectal cancer.